Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a promising company with a strong partnership portfolio in the biopharma industry, which is expected to generate consistent and recurring revenue. With a focus on expanding its customer base, SOPH aims to reach breakeven by 2026 and become profitable by 2027. Their innovative use of AI technology and recent partnerships and offerings are projected to drive growth and have led to a favorable price target increase by analysts.

Bears say

Sophia Genetics is not yet a profitable company, and its potential for future profitability is uncertain despite its strong growth potential in the healthcare technology sector. Additionally, competition in the precision oncology diagnostics market and the need for further investments in product development may hinder its profitability in the near term. Furthermore, the company's valuation appears to be on the lower end compared to historical averages in the sector, possibly due to it being a data software business with high gross margins.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.